Best Blue Chip Stocks this July 2026 in the UK

Currently, there is no financial data available to assess the investment's performance. However, the analyst rating stands at S-, indicating a cautious outlook. Investors should consider these factors when evaluating potential risks and returns.

Coca-Cola boasts a solid dividend yield of 2.57% and impressive returns of 17.49% over the past year and 52.29% over five years, reflecting strong performance and investor confidence. Analysts maintain a favorable outlook with a median 12-month price target of $87.00, supported by recent ratings of "Overweight" from Barclays and Wells Fargo, and a "Buy" from Citigroup. Overall, Coca-Cola's strong fundamentals and consistent dividend growth make it an attractive option for dividend-focused investors.

Coca-Cola shows strong fundamentals, including a 63-year streak of dividend increases and 10% organic revenue growth.

Microsoft's current dividend yield stands at 0.98%, but the stock has faced significant challenges, reflected in a 1-year return of -24.80%. However, over the past five years, it has delivered a solid 38.80% return, indicating potential for long-term growth. Analysts maintain a favorable outlook with a median 12-month price target of $550, despite recent volatility driven by intensified competition and negative sentiment in the software sector.

Microsoft's stock is declining due to negative sentiment in the software sector and increased competition.

The all-time high closing price for Microsoft stock was $538.66 on October 28, 2025, while the 52-week high is $555.45, 46.4% above the current share price.

Visa Inc. offers a modest dividend yield of 0.80%, but its recent 1-year return of -3.55% highlights some short-term challenges, likely influenced by weak consumer sentiment and slowing retail sales. Over the past five years, however, the stock has performed robustly with a 43.63% return, indicating strong long-term potential. With analysts maintaining a favorable outlook, including a median price target of $385.00, investors may find opportunities as the market stabilizes.

V stock is declining due to weak consumer sentiment and slowing retail sales, which contrast with Visa's strong payment processing volumes. Upcoming Q2 results in April will provide more insight into spending trends amid low consumer confidence.

With a modest dividend yield of 0.13%, the stock has delivered impressive returns, boasting a 22.05% gain over the past year and an extraordinary 863.13% over five years. Analysts maintain a strong outlook, with a median 12-month price target of $300.00 and ratings ranging from Buy to Strong Buy, indicating confidence in continued performance. Investors should weigh the potential for substantial capital appreciation alongside the low dividend yield when considering this stock.

With a modest dividend yield of 0.23%, GOOGL has delivered impressive returns, boasting an 88.98% gain over the past year and a remarkable 175.33% over the last five years. Analysts are optimistic, with a median 12-month price target of $420.00 and a strong consensus—88% of analysts recommend buying the stock, indicating robust confidence in its continued performance.

50% of analysts recommend a Strong Buy, while 38% suggest Buy, and 13% advise Holding.

Johnson & Johnson, a leading multinational in the healthcare sector, offers UK investors access to its robust pharmaceutical and medical device portfolio through the NYSE. With a strong dividend yield of 2.28% and impressive returns of 67.09% over the last year, it stands out as an attractive option for those seeking reliable income and growth. Analysts maintain a positive outlook, setting a median 12-month price target of $260.00, reinforcing its status as a top-rated investment opportunity.

The highest closing price for Johnson & Johnson stock was $247.11 on March 2, 2026, while the 52-week high is $251.71.

Warren Buffett's Berkshire Hathaway first invested in Johnson & Johnson in Q1 2006 but completely sold its stake between Q2 2012 and Q3 2023.

With a solid dividend yield of 3.63%, this investment has shown impressive returns of 36.08% over the past year and 31.64% over the last five years. However, recent analyst downgrades, including underweight and hold ratings from major firms, suggest caution, despite a median 12-month price target of $53.00, indicating potential upside. Investors should weigh the attractive yield and historical performance against the current bearish sentiment from analysts.

GSK's strong performance is driven by significant revenue growth across various units, including 17% in Specialty Medicines, 18% in Respiratory, 43% in Oncology, and 11% in HIV products.

The stock offers a dividend yield of 1.82% and has demonstrated strong performance with a 1-year return of 14.61% and an impressive 5-year return of 113.21%. Analysts have a median 12-month price target of $342.00, with a range of $295.00 to $391.00, reflecting a generally favorable outlook, though ratings vary from "Outperform" to "Hold" among key firms. Investors may find the combination of steady dividends and solid growth potential appealing for their portfolios.